CD5 antibody | YKIX322.3

Rat anti Dog CD5:RPE

Product Type
Monoclonal Antibody
Clone
YKIX322.3
Isotype
IgG2a
Specificity
CD5

Product Code Applications Pack Size List Price Your Price Qty
MCA1037PE
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
F 100 Tests/1ml loader
List Price Your Price
loader
Search for Batch Specific Datasheets

Rat anti Dog CD5 antibody, clone YKIX322.3 recognizes canine CD5, a 67 kDa cell surface type 1 transmembrane glycoprotein also known as lymphocyte antigen T1, Ly-1 or Leu-1. CD5 is expressed on the surface of T-cells and thymocytes, CD5 is also expressed by NK cells at low levels (Huang et al. 2008). Rat anti dog CD5, cloneYKIX322.3 was clustered as canine CD5 in the First Canine Leucocyte Antigen Workshop (Cobbold et al. 1994).

In a study of 73 cases of canine chronic lymphocytic leukemia (CLL) CD5 expression was absent on all cases of B-cell CLL as defined by CD21 expression and lack of CD3 or other T cell antigen expression (Vernau and Moore 1999). Rat anti dog CD5 serves as a useful marker for the discrimination of canine leukemias of differing origins (Deravi et al. 2017).

Target Species
Dog
Product Form
Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized.
Reconstitution
Reconstitute with 1.0 ml distilled water.
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant.
Buffer Solution
Phosphate buffered saline.
Preservative Stabilisers
0.09%sodium azide.
1%bovine serum albumin.
5%sucrose.
Immunogen
Concanavilin A activated canine peripheral blood cells
Fusion Partners
Spleen cells from an immunised DA rat were fused with cells of the rat Y3/Ag1.2.3 myeloma cell line
Max Ex/Em
Fluorophore Excitation Max (nm) Emission Max (nm)
RPE 488nm laser 496 578
Regulatory
For research purposes only.
Guarantee
12 months from date of despatch.

Prior to reconstitution store at +4°C. Following reconstitution store at +4°C.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only.It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.
Flow Cytometry
Use 10μl of the suggested working dilution to label 106 cells in 100μl.

How to Use the Spectraviewer

Watch the Tool Tutorial Video ▸
  • Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
  • Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
  • Select the lasers and filters you wish to include
  • Select combined or multi-laser view to visualize the spectra

Description Product Code Applications Pack Size List Price Your Price Quantity
Rat IgG2a Negative Control:RPE MCA1212PE F 100 Tests loader
List Price Your Price
loader
Description Rat IgG2a Negative Control:RPE
Rat IgG2a Negative Control:RPE MCA6005PE F 100 Tests loader
List Price Your Price
loader
Description Rat IgG2a Negative Control:RPE

References for CD5 antibody

  1. Cobbold, S/ & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
    Tissue Antigens. 43 (3): 137-54.
  2. Hewicker-Trautwein, M. et al. (1999) Immunocytochemical demonstration of lymphocyte subsets and MHC class II antigen expression in synovial membranes from dogs with rheumatoid arthritis and degenerative joint disease.
    Vet Immunol Immunopathol. 67 (4): 341-57.
  3. Huang, Y.C. (2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells.
    J Leukoc Biol. 84: 1501-10.
  4. Araújo, M.S. et al. (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis.
    Vet Immunol Immunopathol. 141: 64-75.
  5. Burnett, R.C. et al. (2003) Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes.
    Vet Pathol. 40: 32-41.
  6. Fosmire, S.P. et al. (2007) Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma.
    Vet Pathol. 44: 467-78.
  7. Guarga, J.L. et al. (2002) Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis.
    Vet Immunol Immunopathol. 88: 13-20.
  8. Vernau, W. Moore, P.F. et al. (1999) An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction.
    Vet Immunol Immunopathol. 69: 145-64.
  9. View The Latest Product References
  10. Lamerato-kozicki, A.R. et al. (2006) Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation.
    Exp Hematol. 34 (7): 870-8.
  11. Rütgen BC et al. (2012) Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model.
    PLoS One. 7 (6): e40078.
  12. Aresu, L. et al. (2014) VEGF and MMP-9: biomarkers for canine lymphoma.
    Vet Comp Oncol. 12: 29-36.
  13. Moreira, M.L. et al. (2016) Vaccination against canine leishmaniosis increases the phagocytic activity, nitric oxide production and expression of cell activation/migration molecules in neutrophils and monocytes.
    Vet Parasitol. 220: 33-45.
  14. Gelain, M.E. et al. (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood.
    Vet Immunol Immunopathol. 159 (1-2): 91-6.
  15. Michael, H.T. et al. (2013) Isolation and characterization of canine natural killer cells.
    Vet Immunol Immunopathol. 155 (3): 211-7.
  16. Karayannopoulou, M. et al. (2017) Evaluation of blood T-lymphocyte subpopulations involved in host cellular immunity in dogs with mammary cancer.
    Vet Immunol Immunopathol. 186: 45-50.
  17. Bonnefont-Rebeix, C. et al. (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology.
    Immunobiology. 221 (1): 12-22.
  18. Gibbons, N. et al. (2017) Phenotypic heterogeneity of peripheral monocytes in healthy dogs.
    Vet Immunol Immunopathol. 190: 26-30.
  19. Deravi, N. et al. (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes.
    Vet Immunol Immunopathol. 191: 5-13.
  20. GomesMde, O. et al. (2011) Old beagle dogs have lower faecal concentrations of some fermentation products and lower peripheral lymphocyte counts than young adult beagles.
    Br J Nutr. 106 Suppl 1: S187-90.
  21. MariaA, P.J. et al. (2017) The effect of age and carbohydrate and protein sources on digestibility, fecal microbiota, fermentation products, fecal IgA, and immunological blood parameters in dogs.
    J Anim Sci. 95 (6): 2452-66.
  22. Stokol, T. et al. (2015) Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog.
    Vet Clin Pathol. 44 (1): 79-93.
  23. Martini, V. et al. (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy.
    Res Vet Sci. 125: 130-5.
  24. Lin, C.S. et al. (2018) Activating natural killer (NK) cytotoxicity of canine CD5-CD21- cells requires low surface CD5 density NK cells.
    Iran J Vet Res. 19 (2): 87-95.
  25. Roatt, B.M. et al. (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.
    Front Immunol. 8: 217.
  26. Aricò, A. et al. (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.
    BMC Vet Res. 9: 94.
  27. Aguiar-Soares, R.D.O. et al. (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis.
    Vaccines (Basel). 8 (4)Nov 17 [Epub ahead of print].
  28. Graves, S.S. et al. (2019) Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody.
    Vet Immunol Immunopathol. 211: 10-8.
  29. Ito, D. et al. (2015) A double blinded, placebo-controlled pilot study to examine reduction of CD34 +/CD117 +/CD133 + lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma.
    F1000Res. 4: 42.
  30. Wolf-Ringwall, A. et al. (2020) Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol.
    Vet Comp Oncol. 18 (3): 342-52.
  31. Sayag, D. et al. (2020) Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma.
    Vet Clin Pathol. 49 (3): 476-83.
  32. Lee, J. et al. (2021) Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor.
    Biomed Res Int. 2021: 6690704.
  33. Grudzien, M. et al. (2021) A newly established canine NK-type cell line and its cytotoxic properties.
    Vet Comp Oncol. 19 (3): 567-77.
  34. Lee, S.H. et al. (2021) Safety and immunological effects of recombinant canine IL-15 in dogs.
    Cytokine. 148: 155599.
  35. Karayannopoulou, M. et al. (2022) Effect of major versus minor mastectomy on host immunity in canine mammary cancer
    Vet Immunol Immunopathol. 24 Feb: 110403.
  36. Riccardo, F. et al. (2022) Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
    J Immunother Cancer. 10 (5): e004007. [Epub ahead of print].
  37. Jaensch, S. et al. (2022) Clinicopathologic and immunophenotypic features in dogs with presumptive large granular lymphocyte leukaemia
    Australian Veterinary Journal. [Epub ahead of print].

Flow Cytometry

RRID
AB_324035
View more products with CD5 specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

View all Anti-Dog Products